Send to

Choose Destination
Future Oncol. 2019 Jan;15(3):241-255. doi: 10.2217/fon-2018-0577. Epub 2018 Oct 11.

HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.

Author information

Department of Medicine, University of Alabama Birmingham, 1802 Sixth Avenue, North Pavilion 2540K, Birmingham, AL 35294, USA.


Chemotherapy-induced nausea and vomiting (CINV) may occur during the acute (0-24 h) or delayed (25-120 h) phase following chemotherapy administration. The addition of a neurokinin 1 receptor antagonist to antiemetic regimens containing a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone has resulted in improved CINV prophylaxis. Due to numerous adverse events and hypersensitivity reactions associated with fosaprepitant, a commonly used neurokinin 1 receptor antagonist, there remains an unmet need for better-tolerated formulations. HTX-019, the US FDA-approved polysorbate 80- and synthetic surfactant-free aprepitant injectable emulsion, is bioequivalent to and better tolerated (fewer treatment-emergent adverse events) than fosaprepitant. HTX-019 represents a valuable alternative to fosaprepitant for CINV prophylaxis.


Cinvanti; HTX-019; aprepitant


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center